261.05MMarket Cap-13.42P/E (TTM)
3.505High3.360Low494.89KVolume3.370Open3.390Pre Close1.71MTurnover0.74%Turnover RatioLossP/E (Static)74.80MShares6.35052wk High0.64P/B235.00MFloat Cap2.68552wk Low--Dividend TTM67.34MShs Float23.010Historical High--Div YieldTTM4.28%Amplitude2.160Historical Low3.450Avg Price1Lot Size
OraSure Technologies Stock Forum
OraSure Unveils Major $40M Stock Buyback: Management Signals Strong Confidence
OraSure Announces $40 Million Stock Repurchase Program
Monday, 24th March at 7:30 am
BETHLEHEM, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (the "Company") (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that its Board of Directors has authorized the repurchase of up to $40 million of its common stock over the next twenty-four months, which will be funded from cash on ...
OraSure Announces $40 Million Stock Repurchase Program
OraQuick® HIV Self-Test Now Approved for Use in Adolescents
Tuesday, 7th January at 7:05 am
BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- OraQuick® HIV Self-Test that will increase access to HIV testing for adolescents. The change expands the approved age range to include individuals 14 years of age and older for the OraQuick® HIV Self-Test. Previously the test was approved for use in those 17 and older.
According to the most recent data available from t...
Still, it doesn't look ready quite yet.
OraSure Technologies Acquires Sherlock Biosciences
Thursday, 19th December at 4:02 pm
BETHLEHEM, Pa., Dec. 19, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OTI") (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the acquisition of Sherlock Biosciences, Inc., a global health company bringing next-generation diagnostics to consumers and healthcare providers.
This acquisition expands OraS...
Take a look. See if you like it.
OraSure Receives Federal Funding for Development of Marburg Virus Rapid Antigen Test
OraSure Technologies (NASDAQ: OSUR) has received a federal contract through the Rapid Response Partnership Vehicle (RRPV) to develop a Marburg Virus Disease (MVD) rapid antigen test. The initial contract is valued at $7.5 million over multiple years, with potential value up to $11 million. The funding from BARDA aims to achieve FDA 510(k) clearance for a single-use lateral f...
No comment yet